LifeStance Health has issued a correction notice for a recent press release detailing clinical data on esketamine and TMS treatments, clarifying that the adjustments do not impact the company's financial or operational standing.
Correction notice to a press release about clinical data for esketamine and TMS treatment; no material change to company fundamentals.
LifeStance Health Group issued a formal correction regarding its October 29, 2026, press release concerning clinical outcomes for patients with treatment-resistant depression. The update addresses data points related to esketamine and TMS treatment efficacy, though the company confirms no material changes to its underlying business fundamentals.
No, the company stated that the correction to the clinical data press release does not represent a material change to its business fundamentals.